This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hinkle, G. H. Articles by Lefevre, S. R. Search for Related Content Social Bookmarking                   What's this?

Pharmacy Considerations Related to Radiolabeled Monoclonal Antibodies

Nuclear Pharmacy Services, The Ohio State University Medical Center, 410 West Tenth Ave, Columbus, Oh 43210

Robert W. Beightol

Nuclear Pharmacy Services, The Ohio State University Medical Center, 410 West Tenth Ave, Columbus, Oh 43210

Ned Gregorio

Nuclear Pharmacy Services, The Ohio State University Medical Center, 410 West Tenth Ave, Columbus, Oh 43210

Steven R. Lefevre

Nuclear Pharmacy Services, The Ohio State University Medical Center, 410 West Tenth Ave, Columbus, Oh 43210

Current modalities used for the detection and treatment of cancer suffer from the lack of specificity for tumor cells. Radiolabeled monoclonal antibodies have been, and continue to be, actively investigated for use in this regard. Various radionuclides, cell cultures, and radiolabeling processes have been examined, aimed at producing a product with sufficient immunoreactivity to enhance the use of these agents in various radioimmunodetection, radioimmunotherapy and radioimmunoguided surgery capacities. Antibody production, radiolabeling and radionuclide selection criteria, and quality assessment techniques for radiolabeled monoclonal antibodies are reviewed.

Journal of Pharmacy Practice, Vol. 2, No. 3, 177-184 (1989)
DOI: 10.1177/089719008900200307


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?